SCMH1 Antibody

What is SCMH1 and why is it relevant to research?

SCMH1 (Sex comb on midleg homolog 1) is a polycomb group protein with a molecular mass of approximately 60 kDa that plays an important role in maintaining the transcriptionally repressive state of specific genes . SCMH1 associates with Polycomb group (PcG) multiprotein complexes and functions as a substoichiometric component of PcG complex 1 . Research has demonstrated that SCMH1 possesses E3 ubiquitin ligase activity for both histone H2A and geminin, contributing to transcriptional silencing and geminin stability regulation, respectively . Recent studies have also identified circular RNA forms of SCMH1 (circSCMH1) with therapeutic potential in stroke recovery through mechanisms involving mitophagy inhibition .

Proper validation is critical for reproducible research. According to current standards and symposium recommendations , implement these validation approaches:

• Positive and negative controls:

  • Positive controls: Use cell lines with known SCMH1 expression (HT-1080, U-251 cells show positive WB detection)

  • Negative controls: SCMH1 knockdown/knockout samples or non-expressing tissues

• Multiple antibody validation:

  • Use at least two antibodies targeting different epitopes of SCMH1

  • Compare banding patterns between antibodies in Western blots

• Application-specific validation:

  • For WB: Confirm band at expected molecular weight (~73 kDa predicted, though observed at 58-60 kDa)

  • For IHC: Perform peptide competition assays and compare with mRNA expression patterns

• Orthogonal validation:

  • Correlate protein detection with mRNA expression levels

  • Compare with genetic manipulation (siRNA, CRISPR) results

• Advanced validation for critical studies:

  • Perform immunoprecipitation followed by mass spectrometry

  • Consider using recombinant antibodies with defined epitopes

What are the optimal protocols for using SCMH1 antibodies in Western blotting?

Based on validated experimental protocols from multiple sources :

Sample Preparation:

• Extract protein using RIPA buffer supplemented with protease inhibitors

• For detection of nuclear-localized SCMH1, perform nuclear-cytoplasmic fractionation

• Load 5-20 μg of total protein per lane

Western Blot Protocol:

• Separate proteins on 10-12% SDS-PAGE

• Transfer to PVDF or nitrocellulose membrane (90 minutes at 100V)

• Block with 5% non-fat milk in TBST (1 hour at room temperature)

• Incubate with primary antibody:

  • Anti-SCMH1 monoclonal [OTI5E6] at 1/2000 dilution

  • Anti-SCMH1 polyclonal (11489-1-AP) at 1/500-1/1000 dilution

• Wash 3× with TBST (10 minutes each)

• Incubate with appropriate HRP-conjugated secondary antibody (1/5000 dilution)

• Wash 3× with TBST (10 minutes each)

• Develop using ECL substrate and image

Expected Results:

• Primary band at ~58-73 kDa (predicted: 73 kDa, observed: often ~58-60 kDa)

• Potential additional bands may represent splice variants or post-translational modifications

Troubleshooting Notes:

• If multiple bands appear, increase blocking time or antibody dilution

• For weak signal, extend primary antibody incubation to overnight at 4°C

• If background is high, include 0.05% Tween-20 in antibody dilutions

How should SCMH1 antibodies be used for immunohistochemistry applications?

For optimal immunohistochemistry results with SCMH1 antibodies:

Sample Preparation:

• Use formalin-fixed, paraffin-embedded (FFPE) tissue sections (4-6 μm thickness)

• For SCMH1 detection in tissue samples, antigen retrieval is essential

IHC Protocol:

• Deparaffinize and rehydrate sections

• Perform antigen retrieval:

  • Preferred method: TE buffer pH 9.0

  • Alternative: citrate buffer pH 6.0

  • Heat in pressure cooker or microwave for 20 minutes

• Block endogenous peroxidase (3% H₂O₂ for 10 minutes)

• Block non-specific binding (5% normal serum, 1 hour)

• Apply primary antibody:

  • Anti-SCMH1 monoclonal [OTI5E6] at 1/150 dilution

  • Anti-SCMH1 polyclonal (11489-1-AP) at 1/20-1/200 dilution

• Incubate overnight at 4°C

• Apply appropriate secondary antibody and detection system

• Counterstain, dehydrate, and mount

Tissue-specific Recommendations:

• Positive controls: Pancreatic cancer tissue shows reliable detection

• SCMH1 is highly expressed in testis tissue

• When examining spermatocytes, note that SCMH1 is excluded from the XY body at late pachytene

How can I design experiments to study SCMH1 in complex with other Polycomb group proteins?

When investigating SCMH1's interactions with Polycomb complex components:

Co-immunoprecipitation Strategy:

• Use anti-SCMH1 antibodies suitable for IP applications (e.g., monoclonal 7-RY14)

• Cross-link antibodies to protein A/G beads to prevent antibody contamination

• Incubate cell lysates with antibody-coupled beads (4 hours or overnight at 4°C)

• Wash extensively with buffer containing 0.1% NP-40

• Elute and analyze by Western blotting for PcG complex 1 components including:

  • Phc1, Phc2

  • Rnf110 (Pcgf2)

  • Bmi1

  • Cbx2

Additional Methodological Considerations:

• Use nuclear extraction protocols to enrich for chromatin-associated complexes

• Consider protein crosslinking to stabilize transient interactions

• For substoichiometric components like SCMH1, increase starting material

• Control for cell cycle phase, as SCMH1 association with PcG bodies is cell cycle-dependent

How can I investigate SCMH1's E3 ubiquitin ligase activity in experimental systems?

SCMH1 has been identified as an E3 ubiquitin ligase for both geminin and histone H2A . To study this activity:

In Vitro Ubiquitination Assay:

• Express and purify recombinant SCMH1 (full-length or catalytic domain)

• Set up ubiquitination reaction containing:

  • E1 activating enzyme

  • E2 conjugating enzyme

  • Recombinant SCMH1 (E3)

  • Purified substrate (geminin or histone H2A)

  • Biotinylated or tagged ubiquitin

  • ATP regeneration system

• Incubate at 37°C for 1-2 hours

• Analyze by Western blotting for substrate-ubiquitin conjugates

Cell-based Ubiquitination Analysis:

• Transfect cells with HA-tagged ubiquitin and SCMH1 (wild-type or mutant)

• Treat with proteasome inhibitor (MG132) for 4-6 hours

• Lyse cells under denaturing conditions

• Immunoprecipitate substrate (geminin or H2A)

• Western blot for ubiquitin conjugates

Regulatory Analysis:

• SCMH1 itself is regulated through the ubiquitin-proteasome system

• Investigate the paradoxical relationship where SCMH1 mutants lead to decreased geminin levels, possibly through derepression of Hoxa9 and Hoxb4 increasing RDCOX E3 ligase activity

What approaches can be used to study the relationship between SCMH1 and circSCMH1 in ischemic stroke models?

Recent studies have revealed important roles for circular RNA SCMH1 (circSCMH1) in stroke recovery . To investigate this:

CircSCMH1 Expression Analysis:

• Design primers specific for circSCMH1 back-splice junctions

• Use RNase R treatment to enrich for circular RNAs

• Perform qRT-PCR to quantify circSCMH1 levels in:

  • Patient plasma samples (decreased in acute ischemic stroke)

  • Peri-infarct cortex of photothrombotic stroke mice

Functional Studies Using Brain-Targeting Delivery Systems:

• Generate rabies virus glycoprotein (RVG)-circSCMH1-extracellular vesicles for brain-targeted delivery

• Administer to stroke models (mouse and non-human primate models have been validated)

• Evaluate:

  • Functional recovery using behavioral tasks

  • Neuroplasticity markers

  • Glial activation and peripheral immune cell infiltration

Mechanistic Investigation:

• Study circSCMH1's inhibition of KMO expression:

  • RNA pull-down assays using biotinylated circSCMH1 probe

  • ChIP experiments to examine STAT5B binding to KMO promoter

  • Nuclear/cytoplasmic fractionation to track STAT5B localization

• Analyze mitochondrial dynamics:

  • Assess OPA1 and MFN2 expression levels

  • Examine mitochondrial morphology using immunofluorescence

  • Measure LC3B-II and SQSTM1 as autophagosome formation markers

How can I optimize bispecific antibody approaches for precise quantification of SCMH1 in complex biological samples?

For researchers aiming to precisely quantify SCMH1 in complex samples, bispecific antibody technology offers significant advantages :

Bispecific Antibody Design Considerations for SCMH1:

• Choose from established formats:

  • Fab-scFv construct (monovalent for antigen binding)

  • IgG with C-terminal scFv fusion

• Design strategy:

  • Incorporate SCMH1-specific binding domain

  • Add hapten-binding domain (e.g., digoxigenin) for quantitative labeling

  • Consider connector design (glycine-serine motif has shown efficacy)

Quantitative Flow Cytometry Protocol:

• Prepare cells with SCMH1 expression

• Incubate with bispecific antibody (1 μg/10^6 cells)

• Wash to remove unbound antibody

• Add fluorophore-conjugated hapten at saturating concentration

• Analyze by flow cytometry

• Quantify using calibration beads with known antibody binding capacity

Advantages of This Approach:

• Precise 1:1 antibody-to-antigen ratio for accurate quantitation

• Site-specific labeling without affecting binding properties

• Flexibility to use different fluorophores with the same antibody preparation

• Reduced risk of unwanted Fc receptor binding

How can I address non-specific binding and background issues when using SCMH1 antibodies?

Non-specific binding is a common challenge with antibodies. For SCMH1-specific troubleshooting:

Western Blot Background Issues:

• Increase blocking stringency:

  • Extend blocking time to 2 hours

  • Use 5% BSA instead of milk for phospho-specific detection

  • Add 0.1-0.3% Tween-20 to reduce hydrophobic interactions

• Optimize antibody dilutions:

  • Test serial dilutions of primary antibody (1:500 to 1:2000)

  • Increase secondary antibody dilution (1:5000 to 1:10000)

• Perform additional washing steps:

  • Increase wash duration (15 minutes per wash)

  • Add low concentration (50-150 mM) of NaCl to wash buffer

Immunohistochemistry Background Reduction:

• Optimize antigen retrieval:

  • Compare TE buffer pH 9.0 with citrate buffer pH 6.0

  • Adjust retrieval time (10-30 minutes)

• Block endogenous enzymes:

  • For peroxidase detection, use 3% H₂O₂ in methanol

  • For alkaline phosphatase, use levamisole

• Reduce non-specific binding:

  • Use species-specific serum matching secondary antibody

  • Add 0.1-0.3% Triton X-100 for better antibody penetration

  • Consider protein-free blockers if protein cross-reactivity occurs

What strategies can address issues with reproducibility when using SCMH1 antibodies across experiments?

Antibody reproducibility remains a major challenge, with approximately 50% of biomedical researchers reporting difficulties reproducing findings . For SCMH1-specific reproducibility:

Documentation and Standardization:

• Maintain detailed antibody records:

  • Catalog number and lot number

  • Validation data for each lot

  • Storage conditions and freeze-thaw cycles

• Standardize experimental protocols:

  • Use consistent cell lysis methods

  • Standardize protein quantification

  • Maintain consistent antibody dilutions and incubation times

Quality Control Practices:

• Include positive and negative controls in each experiment

• Prepare master mixes of antibody dilutions for technical replicates

• Consider using recombinant antibodies with defined sequences

• For critical experiments, validate using orthogonal methods:

  • Compare with RNA expression data

  • Utilize genetic manipulation (siRNA, CRISPR)

  • Consider mass spectrometry validation

Multi-antibody Approach:

• Use at least two independent antibodies targeting different SCMH1 epitopes

• Compare results between monoclonal and polyclonal antibodies

• Consider using recombinant Fab fragments that recognize folded domains

What factors should be considered when analyzing SCMH1 expression in different cell types and tissues?

SCMH1 expression and function vary across tissues and cellular contexts:

Tissue-Specific Expression Patterns:

• Highly expressed in testis tissue

• Shows distinct localization patterns during spermatocyte development

• Expression in brain tissue is relevant for stroke research

Subcellular Localization Considerations:

• SCMH1 contains nuclear localization signals

• Shows cell cycle-dependent association with PcG bodies

• In late pachytene spermatocytes, SCMH1 is excluded from the XY body

Technical Considerations for Different Sample Types:

• For nuclear proteins:

  • Use nuclear extraction protocols

  • Include phosphatase inhibitors to preserve modification state

• For tissue samples:

  • Optimize fixation time for preserved epitopes

  • Consider using fresh frozen samples for sensitive epitopes

• For brain tissue:

  • Perfusion fixation improves antibody penetration

  • Use antigen retrieval methods optimized for neural tissue

How can SCMH1 antibodies be employed in studying the role of circSCMH1 in neuroprotection?

Recent studies have revealed circSCMH1's therapeutic potential in stroke recovery . To investigate this further:

Experimental Approaches:

• Combined protein-RNA analysis:

  • Use SCMH1 antibodies for protein detection alongside circSCMH1 RNA analysis

  • Correlate protein levels with circular RNA expression

  • Examine how circSCMH1 therapy affects SCMH1 protein expression

• Target validation studies:

  • Use antibodies against downstream targets (KMO, STAT5B)

  • Examine mitochondrial dynamics markers (OPA1, MFN2)

  • Assess mitophagy markers (LC3B-II, SQSTM1)

• Therapeutic development:

  • Monitor efficacy of RVG-circSCMH1-EV treatment using biomarkers

  • Investigate protein interactions using co-IP with SCMH1 antibodies

  • Evaluate glial activation using immunofluorescence

Key Findings to Build Upon:

• CircSCMH1 binds STAT5B and inhibits its nuclear translocation

• This inhibition suppresses KMO expression, enhancing mitochondrial fusion and inhibiting mitophagy

• Treatment improves functional recovery in both mouse and non-human primate stroke models

What are the latest advances in single-chain variable fragment (scFv) antibody technology for studying SCMH1?

Single-chain variable fragments offer several advantages for structural and functional studies of SCMH1:

Structural Biology Applications:

• scFv constructs improved cryo-EM analysis of protein complexes by preventing preferred orientations

• VL-VH orientation (with (GGGGS)₃ linker) showed better inclusion-body yield and refolding efficiency than VH-VL

Design Considerations:

• Orientation selection:

  • Test both VH-linker-VL and VL-linker-VH configurations

  • Evaluate expression yields and binding affinity for each

  • Consider disulfide stabilization for improved stability

• Expression systems:

  • E. coli systems allow cost-effective production but may have lower yields

  • Mammalian expression systems (HEK293T) produce higher quality scFvs with proper folding

  • Binding affinity should be validated (e.g., using SPR analysis)

• Applications beyond structural biology:

  • Intracellular expression for protein function disruption

  • Fusion to fluorescent proteins for live-cell imaging

  • Development of bispecific detection reagents

How can we integrate SCMH1 antibody data with multi-omics approaches for comprehensive functional analysis?

For researchers seeking to build comprehensive understanding of SCMH1 biology:

Integrated Multi-omics Workflow:

• Protein-centric approaches:

  • Use SCMH1 antibodies for protein localization and expression analysis

  • Perform IP-MS to identify protein interaction networks

  • Use ChIP-seq to map genomic binding sites of SCMH1

• Integration with transcriptomics:

  • Correlate SCMH1 protein levels with gene expression data

  • Examine effects of SCMH1 modulation on transcriptional profiles

  • Analyze circSCMH1 expression in parallel with linear transcript levels

• Metabolomics integration:

  • Recent work identified significant metabolic changes after circSCMH1 treatment

  • 346 metabolites changed significantly in photothrombotic mice after treatment

  • Most altered metabolites were associated with amino acid metabolic pathways

Data Analysis Framework:

• Use pathway enrichment analysis to connect protein-level findings with metabolic changes

• Perform network analysis to identify key nodes connecting SCMH1 to metabolic processes

• Consider temporal dynamics when integrating datasets from different timepoints